

January 14, 2025

**Stronger Together: Merger of In2Pharma, KDT Consulting, Studio Pharma and acquisition of Farmaconsult.**

The companies **In2Pharma**, **KDT Consulting** and **Studio Pharma** joined forces on 1 January 2025. After more than 20 years of successful separate activities in pharmaceutical consulting in the Benelux, they will continue together as one solid group. As of April 1th 2026, the different operational entities have officially merged into IN2Pharma

This merger, simultaneous with the acquisition of Farmaconsult, is an important step in our development and enables us to support our clients even better in the ever-changing industry. With a team of more than 25 experienced employees, the newly merged group is one of the leading independent consulting companies in the Benelux. This in the areas of Regulatory Affairs, Quality Assurance, Medical Affairs, Pricing & Reimbursement, Information & Publicity and Pharmacovigilance.

In addition to creating economies of scale, this merger provides a solid foundation for future growth and innovation, while remaining true to our values: high quality work, customer focus, flexibility and a strong focus on collaboration. Together, we will be even better able to respond to new evolutions, guarantee service continuity and expand our range of consultancy services in the future, providing our clients with the flexible and efficient support they are used to and need from us in order to excel.

Driven by a shared vision and common mission, this merger unites four highly complementary companies and cultures, each with a reputation for quality and customer satisfaction.

If you have any questions or would like to know more about what this merger could mean for you, please do not hesitate to contact Caroline Steensels (csteensels@in2pharma.com / +32 477 30 68 53), or Isabelle Geeraert (igeeraert@in2pharma.com / + 32 496 85 87 49).


We are excited to embark on this new phase with you and remain steadfast in our commitment to your success.



**Caroline Steensels**  
In2Pharma NV



**Lode Asselman**  
KDT Consulting BV



**Isabelle Geeraert**  
Studio Pharma BV